MoonLake Immunotherapeutics Operating Lease, Right-of-Use Asset in USD from Q4 2021 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of lessee's right to use underlying asset under operating lease.
Summary
MoonLake Immunotherapeutics quarterly Operating Lease, Right-of-Use Asset history and growth rate from Q4 2021 to Q3 2025.
  • MoonLake Immunotherapeutics Operating Lease, Right-of-Use Asset for the quarter ending September 30, 2025 was $1.91M, a 41.2% decline year-over-year.
Operating Lease, Right-of-Use Asset, Quarterly (USD)
Operating Lease, Right-of-Use Asset, YoY Quarterly Growth (%)

MoonLake Immunotherapeutics Quarterly Operating Lease, Right-of-Use Asset (USD)

Period Value YoY Chg Change % Date Report Filed
Q3 2025 $1.91M -$1.34M -41.2% Sep 30, 2025 10-Q 2025-11-05
Q2 2025 $2.25M -$1.13M -33.5% Jun 30, 2025 10-Q 2025-08-05
Q1 2025 $2.59M -$1.11M -30% Mar 31, 2025 10-Q 2025-05-12
Q4 2024 $2.92M -$706K -19.5% Dec 31, 2024 10-Q 2025-11-05
Q3 2024 $3.25M +$3.08M +1819% Sep 30, 2024 10-Q 2024-11-07
Q2 2024 $3.38M +$3.17M +1502% Jun 30, 2024 10-Q 2024-08-07
Q1 2024 $3.7M +$3.45M +1402% Mar 31, 2024 10-Q 2024-05-07
Q4 2023 $3.63M +$3.35M +1184% Dec 31, 2023 10-K 2025-02-26
Q3 2023 $169K Sep 30, 2023 10-Q 2023-11-14
Q2 2023 $211K Jun 30, 2023 10-Q 2023-08-10
Q1 2023 $246K Mar 31, 2023 10-Q 2023-05-11
Q4 2022 $283K +$283K Dec 31, 2022 10-K 2024-02-29
Q4 2021 $0 Dec 31, 2021 10-K 2023-03-20
* An asterisk sign (*) next to the value indicates that the value is likely invalid.